Related Experiment Video
Updated: Apr 20, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics
Xu Zhang1, Natalya Belkina, Harrys Kishore Charles Jacob
1Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Abstract:
Mutations in the epidermal growth factor receptor (EGFR) kinase domain occur in 10-30% of lung adenocarcinoma and are associated with tyrosine kinase inhibitor (TKI) sensitivity. We sought to identify the immediate direct and indirect phosphorylation targets of mutant EGFRs in lung adenocarcinoma. We undertook SILAC strategy, phosphopeptide enrichment, and quantitative MS to identify dynamic changes of phosphorylation downstream of mutant EGFRs in lung adenocarcinoma cells harboring EGFR(L858R) and EGFR(L858R/T790M) , the TKI-sensitive, and TKI-resistant mutations, respectively. Top canonical pathways that were inhibited upon erlotinib treatment in sensitive cells, but not in the resistant cells include EGFR, insulin receptor, hepatocyte growth factor, mitogen-activated protein kinase, mechanistic target of rapamycin, ribosomal protein S6 kinase beta 1, and Janus kinase/signal transducer and activator of transcription signaling. We identified phosphosites in proteins of the autophagy network, such as ULK1 (S623) that is constitutively phosphorylated in these lung adenocarcinoma cells; phosphorylation is inhibited upon erlotinib treatment in sensitive cells, but not in resistant cells. Finally, kinase-substrate prediction analysis from our data indicated that substrates of basophilic kinases from, AGC and Calcium and calmodulin-dependent kinase groups, as well as STE group kinases were significantly enriched and those of proline-directed kinases from, CMGC and Casein kinase groups were significantly depleted among substrates that exhibited increased phosphorylation upon EGF stimulation and reduced phosphorylation upon TKI inhibition. This is the first study to date to examine global phosphorylation changes upon erlotinib treatment of lung adenocarcinoma cells and results from this study provide new insights into signaling downstream of mutant EGFRs in lung adenocarcinoma. All MS data have been deposited in the ProteomeXchange with identifier PXD001101 (http://proteomecentral.proteomexchange.org/dataset/PXD001101).
Insights
This study identifies key phosphorylation targets affected by mutant epidermal growth factor receptor (EGFR) in lung adenocarcinoma. It reveals how erlotinib treatment impacts signaling pathways in TKI-sensitive versus TKI-resistant cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in lung adenocarcinoma, influencing sensitivity to tyrosine kinase inhibitors (TKIs).
- Understanding the downstream phosphorylation events regulated by mutant EGFR is crucial for developing effective targeted therapies.
Purpose of the Study:
- To identify the immediate direct and indirect phosphorylation targets of mutant EGFRs in lung adenocarcinoma.
- To compare the phosphorylation changes in TKI-sensitive versus TKI-resistant lung adenocarcinoma cells upon erlotinib treatment.
Main Methods:
- Utilized SILAC (Stable Isotope Labeling by Amino acids in Cell culture) strategy for quantitative proteomics.
- Employed phosphopeptide enrichment and mass spectrometry (MS) to identify dynamic phosphorylation changes.
- Analyzed signaling pathways and kinase-substrate relationships affected by mutant EGFR and TKI treatment.
Main Results:
- Identified distinct phosphorylation patterns downstream of TKI-sensitive (EGFR(L858R)) and TKI-resistant (EGFR(L858R/T790M)) mutations.
- Erlotinib treatment inhibited key signaling pathways (EGFR, MAPK, mTOR, JAK/STAT) in sensitive cells but not in resistant cells.
- Discovered constitutive phosphorylation of ULK1 (S623) in the autophagy network, which was sensitive to erlotinib in sensitive cells.
Conclusions:
- This study provides the first global view of phosphorylation changes upon erlotinib treatment in lung adenocarcinoma cells with mutant EGFR.
- The findings offer new insights into the signaling networks regulated by mutant EGFR, differentiating between TKI-sensitive and TKI-resistant phenotypes.
- The data highlights potential therapeutic targets and mechanisms of resistance in EGFR-mutated lung adenocarcinoma.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...